March 19, 2019 / 12:55 PM / 3 months ago

BRIEF-AbbVie Says FDA Placed A Partial Clinical Hold On All Clinical Trials Evaluating Venetoclax For Investigational Treatment Of Multiple Myeloma

March 19 (Reuters) - AbbVie Inc:

* ABBVIE PROVIDES UPDATE ON VENCLEXTA®/VENCLYXTO® (VENETOCLAX) MULTIPLE MYELOMA PROGRAM

* ABBVIE INC - FDA HAS PLACED A PARTIAL CLINICAL HOLD ON ALL CLINICAL TRIALS EVALUATING VENETOCLAX FOR INVESTIGATIONAL TREATMENT OF MULTIPLE MYELOMA

* ABBVIE INC - PARTIAL CLINICAL HOLD FOLLOWS A REVIEW OF DATA FROM ONGOING PHASE 3 BELLINI TRIAL (M14-031)

* ABBVIE INC - TUESDAY'S ACTION DOES NOT IMPACT ANY OF APPROVED INDICATIONS FOR VENETOCLAX

* ABBVIE - PATIENTS WHO ARE CURRENTLY ENROLLED IN STUDIES AND RECEIVING BENEFIT FROM THERAPY MAY CONTINUE WITH TREATMENT, AFTER CONSULTATION WITH PHYSICIAN

* ABBVIE INC - INFORMED CLINICAL TRIAL INVESTIGATORS INVOLVED IN STUDIES OF RESULTS AND WILL WORK WITH THEM TO PROCEED AS APPROPRIATE

* ABBVIE - A HIGHER PROPORTION OF DEATHS WAS OBSERVED IN VENETOCLAX ARM COMPARED TO CONTROL ARM OF TRIAL IN PHASE 3 BELLINI TRIAL (M14-031) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below